Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Watch-and-wait for dMMR LARC with a clinical complete response to dostarlimab

David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the approach to watch-and-wait surveillance for a patient with mismatch repair deficient (dMMR) locally advanced rectal cancer (LARC) who has achieved a clinical complete response on dostarlimab, outlining the use of regular endoscopy, rectal MRI, and CT scans to monitor for disease progression. Dr Tougeron highlights the importance of frequent evaluations, typically every three months, for at least two years, with the possibility of extending the surveillance interval to every six months thereafter. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.